Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

References

• Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan;27(1):55–62.
   PubMed Web of Science ®Google Scholar
• Demoruelle MK, Deane KD. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep. 2012 Oct;14(5):472–480.
   PubMed Web of Science ®Google Scholar
• Verschueren P, De Cock D, Corluy L, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of careRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017 Feb 17;76(3):511–520.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Palamar D, Er G, Terlemez R, et al. Disease activity, handgrip strengths, and hand dexterity in patients with rheumatoid arthritis. Clin Rheumatol. 2017 Oct;36(10):2201–2208.
   PubMed Web of Science ®Google Scholar
• Rosa-Gonçalves D, Bernardes M, Costa L. Quality of life and functional capacity in patients with rheumatoid arthritis cross-sectional study. Reumatol Clin. 2017 Apr;pii:S1699-258X(17)30056-6 [Epub ahead of print]. [Epub ahead of print].
   Google Scholar
• Amador-Patarroyo MJ, Rodriguez-Rodriguez A, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis. 2012;2012:251730.
   PubMedGoogle Scholar
• Barrett EM, Scott DGI, Wiles NJ, et al. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community‐based study. Rheumatology. 2000 Dec;39(12):1403–1409.
   PubMed Web of Science ®Google Scholar
• Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S71–S74.
   PubMedGoogle Scholar
• Manders SHM, Kievit W, Braakman-Jansen ALMA, et al. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors. J Rheumatol. 2014 Jul;41(7):1263–1269.
   PubMed Web of Science ®Google Scholar
• van Jaarsveld CH, Jacobs JW, Schrijvers AJ, et al. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol. 1998 Aug;37(8):848–853.
   PubMedGoogle Scholar
• Westhoff G, Listing J, Zink A. Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care. Arthritis Care Res. 2000 Feb;13(1):11–22.
   PubMed Web of Science ®Google Scholar
• Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the abatacept in inadequate responders to methotrexate (AIM) trial. Clin Ther. 2008 Apr;30(4):734–748.
   PubMed Web of Science ®Google Scholar
• Li T, Wells G, Westhovens R, et al. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Value Health. 2011 Mar-Apr;14(2):361–370.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Boonen A, Verbruggen L, et al. Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol. 2005 Nov;24(6):615–619.
   PubMed Web of Science ®Google Scholar
• Chevreul K, Haour G, Lucier S, et al. Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation an economic analysis based on the ESPOIR cohort. PLoS One. 2014 May 8;9(5):e97077.
   PubMed Web of Science ®Google Scholar
• Huscher D, Mittendorf T, Von Hinüber U, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis. 2015 Apr;74(4):738–745.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol. 2007 May;19(3):272–276.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008 Jan;8(2):49–60.
   Web of Science ®Google Scholar
• Raciborski F, Kłak A, Kwiatkowska B. Indirect costs of rheumatoid arthritis. Reumatologia. 2015;53(5):268–275.
   PubMedGoogle Scholar
• Emery P, Bingham CO, Burmester GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017;76:96–104.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009 Jun;68(6):805–811.
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde DVD, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two–week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008 Nov;58(11):3319–3329.
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 Jun;68(6):797–804.
   PubMed Web of Science ®Google Scholar
• Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11(6):R170–R170.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res. 2009 Nov 15;61(11):1592–1600.
   Web of Science ®Google Scholar
• Kavanaugh A, Gladman D, van der Heijde D, et al. Long-term improvements in workplace and household productivity and social participation over 4 years of certolizumab pegol treatment in patients with psoriatic arthritis, with and without prior anti-tnf exposure. Value Health. 2016 Nov;19(7):A545.
   Web of Science ®Google Scholar
• van der Heijde D, Braun J, Rudwaleit M, et al. SAT0389 long-term improvements in workplace and household productivity and social participation over 4 years of certolizumab pegol treatment in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2016 Jul 15;75(Suppl 2):809.
   Google Scholar
• Curtis JR, Churchill M, Kivitz A, et al. A randomized trial comparing disease activity measures for the assessment and prediction of response in rheumatoid arthritis patients initiating certolizumab pegol. Arthritis Rheumatol. 2015;67(12):3104–3112.
   PubMed Web of Science ®Google Scholar
• EMA.Certolizumab Pegol Summary of Product Characteristics (SmPC). 2009.
   Google Scholar
• Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific work productivity survey (WPS-RA). Arthritis Res Ther. 2009;11(3):R73–R73.
   PubMed Web of Science ®Google Scholar
• Fransen J, Creemers MCW, Van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology. 2004 Oct;43(10):1252–1255.
   PubMed Web of Science ®Google Scholar
• Vrijhoef HJM, Diederiks JPM, Spreeuwenberg C, et al. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 May 1;62(5):419–422.
   PubMed Web of Science ®Google Scholar
• Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(Suppl 39):S93–S99.
   PubMedGoogle Scholar
• Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980 Feb;23(2):137–145.
   PubMed Web of Science ®Google Scholar
• de Vries J, Michielsen H, Van Heck GL, et al. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS). Br J Health Psychol. 2004 Sep 9;9(3):279–291.
   PubMedGoogle Scholar
• Bessette L, Bensen W, Chow A, et al. Certolizumab Pegol Improves Productivity at Paid Work and Within the Household in Adult Rheumatoid Arthritis Patients in Daily Practice in Canada: Interim Analysis of the Observational Non-interventional FαsT CAN Study2013.
   Google Scholar
• Kim D, Kaneko Y, Takeuchi T. Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis. J Rheumatol. 2017 Aug;44(8):1112–1117.
   PubMed Web of Science ®Google Scholar
• Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014 Feb 21;16(1):R56–R56.
   PubMed Web of Science ®Google Scholar
• Mlcoch T, Jircikova J, Mandelikova M, et al. PMS89 the impact of anti-tnf (etanercept) therapy on work productivity in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in the czech republic. Value Health. 2015;18(7):A649.
   PubMedGoogle Scholar
• Takeuchi T, Nakajima R, Komatsu S, et al. Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv Ther. 2017 Mar;34(3):686–702.
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74:96–103.
   PubMed Web of Science ®Google Scholar
• Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19–27.
   PubMed Web of Science ®Google Scholar
• Burmester G, Müller-Ladner U, Nüsslein H, et al., editors. Nicht-interventionelle Studie FαsT: schnelle Verbesserung der patienten-relevanten Outcomes (PRO) mit CERTOLIZUMAB PEGOL zur Behandlung der rheumatoiden Arthritis im deutschen Praxisalltag (Poster RA.21). 42nd Congress of the German Society of Rheumatology; 2014; Düsseldorf, Germany.
   Google Scholar
• Chatzidionysiou K, Kristensen L-E, Eriksson J, et al. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol. 2015;44(6):431–437.
   PubMed Web of Science ®Google Scholar
• Kruger K, Burmester GR, Wassenberg S, et al. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open. 2018;8(6):e021082.
   PubMed Web of Science ®Google Scholar
• van Vilsteren M, Boot CRL, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015 May;6(16):107.
   Google Scholar